Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Intangibles (2019 - 2020)

Historic Change in Intangibles for Summit Therapeutics (SMMT) over the last 4 years, with Q3 2020 value amounting to -$168000.0.

  • Summit Therapeutics' Change in Intangibles fell 24237.29% to -$168000.0 in Q3 2020 from the same period last year, while for Jun 2021 it was -$168000.0, marking a year-over-year decrease of 20848.78%. This contributed to the annual value of $136000.0 for FY2019, which is N/A changed from last year.
  • Latest data reveals that Summit Therapeutics reported Change in Intangibles of -$168000.0 as of Q3 2020, which was down 24237.29% from $4000.0 recorded in Q2 2020.
  • In the past 5 years, Summit Therapeutics' Change in Intangibles ranged from a high of $164000.0 in Q1 2020 and a low of -$896492.0 during Q4 2017
  • Moreover, its 4-year median value for Change in Intangibles was -$6831.7 (2018), whereas its average is -$115412.4.
  • The largest annual percentage gain for Summit Therapeutics' Change in Intangibles in the last 5 years was 24237.29% (2020), contrasted with its biggest fall of 24237.29% (2020).
  • Over the past 4 years, Summit Therapeutics' Change in Intangibles (Quarter) stood at -$896492.0 in 2017, then skyrocketed by 99.26% to -$6663.4 in 2018, then plummeted by 1868.12% to -$131143.9 in 2019, then dropped by 28.1% to -$168000.0 in 2020.
  • Its Change in Intangibles stands at -$168000.0 for Q3 2020, versus $4000.0 for Q2 2020 and $164000.0 for Q1 2020.